



Haleon plc: 2024 Q3 Trading Statement

31 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its Q3 trading update for the year ending 31 December 2024 is available at: http://www.ms-pdf.londonstockexchange.com/ms/3035K_1-2024-10-30.pdf

The Q3 trading update will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

Presentation for analysts and shareholders

A short presentation followed by Q&A will be hosted by Tobias Hestler, Chief Financial Officer at 9:00am GMT (10:00am CET) on 31 October 2024, which can be accessed at www.haleon.com/investors/.

For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:

UK: +44 800 358 1035
US: +1 855 979 6654
All other: +44 20 3936 2999
Passcode: 401552

An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.

Amanda Mellor
Company Secretary

Enquiries

Investors

Rakesh Patel +44 7552 484646
Emma White +44 7823 523562

Media

Zoë Bird +44 7736 746167
Gemma Thomas +44 7985 175048

Email: investor-relations@haleon.com

Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

QRTQKKBNODBKN